Scarica l'app Stockscreener
30.43
8.18%
-2.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$33.14
Aprire:
$33.91
Volume 24 ore:
1.88M
Relative Volume:
1.61
Capitalizzazione di mercato:
$2.52B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-16.81
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
-6.08%
1M Prestazione:
+24.05%
6M Prestazione:
+19.38%
1 anno Prestazione:
-4.19%
Intervallo 1D:
$30.19
$33.91
Intervallo di 1 settimana:
$30.19
$35.25
Portata 52W:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
30.43 | 2.52B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies - Benzinga India
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $330,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cathie Wood’s ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Significant Decline in Short Interest - MarketBeat
Baillie Gifford & Co. Cuts Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Peregrine Investment Management Inc. Takes $3.93 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 17.9%Here's What Happened - MarketBeat
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Nigeria
Next Generation Genome Editing Market Top Companies Study - openPR
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys Shares of 13,287 Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - MSN
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(BEAM) Technical Data - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? - Yahoo Finance
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Stock Price, News & Analysis - MarketBeat
BMO Capital maintains Outperform on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading 8% HigherShould You Buy? - MarketBeat
FY2026 Earnings Estimate for BEAM Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for BEAM Q1 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beam Therapeutics Inc Azioni (BEAM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Option Exercise |
7.22 |
10,000 |
72,200 |
112,968 |
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Sale |
34.00 |
10,000 |
340,000 |
102,968 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):